Synthesis and SARs study of novel spiro‐oxindoles as potent antiproliferative agents with CDK‐2 inhibitory activities
Archiv der Pharmazie · 2023
DOI: 10.1002/ardp.202300185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Refaah Mousa Al-Jassas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Researchers Supporting Project.
Abstract (Originalsprache)
A series of 16 novel spirooxindole analogs 8a–p were designed and constructed via cost‐effective single‐step multicomponent [3+2] cycloaddition reaction of azomethine ylide (AY) generated in situ from substituted isatin ( 6a–d ) with suitable amino acids ( 7a–c ) and ethylene‐engrafted pyrazole derivatives ( 5a,b ). The potency of all compounds was assayed against a human breast cancer cell line (MCF‐7) and a human liver cell line (HepG2). Spiro compound 8c was the most active member among the synthesized candidates, with exceptional cytotoxicity against the MCF‐7 and HepG2 cell lines, with IC 50 values of 0.189 ± 0.01 and 1.04 ± 0.21 µM, respectively. The candidate 8c exhibited more potent activity (10.10‐ and 2.27‐fold) than the standard drug roscovitine (IC 50 = 1.91 ± 0.17 µM (MCF‐7) and 2.36 ± 0.21 µM (HepG2)). Compound 8c was investigated for epidermal growth factor receptor (EGFR) inhibition; it exhibited promising IC 50 values of 96.6 nM compared with 67.3 nM for erlotinib. The IC 50 value of 8c (34.98 nM) exhibited cyclin‐dependent kinase 2 (CDK‐2) inhibition, being more active than roscovitine the (IC 50 = 140 nM) in targeting the CDK‐2 kinase enzyme. Additionally, for apoptosis induction of compound 8c in MCF‐7, it upregulated the expression levels of proapoptotic genes for P53, Bax, caspases‐3, 8, and 9 at up to 6.18, 4.8, 9.8, 4.6, 11.3 fold‐change, respectively, and downregualted the level of the antiapoptotic gene for Bcl‐2 by 0.14‐fold. Finally, a molecular docking study of the most active compound 8c highlighted a good binding affinity with Lys89 as the key amino acid for CDK‐2 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, King Saud University, Riyadh, Saudi Arabia.
- Department of Chemistry (Biochemistry program), Faculty of Science, Suez Canal University, Ismailia, Egypt.
- Department of Chemistry, University of Jyväskylä, Jyväskylä, Finland.
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Förderung
- Researchers Supporting Project
Zitieren
APA
Al-Jassas, R. M., Islam, M. S., Al-Majid, A. M., Nafie, M. S., Haukka, M., Rahman, A. F. M. M., Alayyaf, A. M. A., & Barakat, A. (2023). Synthesis and SARs study of novel spiro‐oxindoles as potent antiproliferative agents with CDK‐2 inhibitory activities. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300185
Vancouver
Al-Jassas RM, Islam MS, Al-Majid AM, Nafie MS, Haukka M, Rahman AFMM, et al. Synthesis and SARs study of novel spiro‐oxindoles as potent antiproliferative agents with CDK‐2 inhibitory activities. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300185
BibTeX
@article{AlJassas2023,
author = {Al-Jassas, Refaah Mousa and Islam, Mohammad Shahidul and Al-Majid, Abdullah Mohammed and Nafie, Mohamed S and Haukka, Matti and Rahman, A F M Motiur and Alayyaf, Abdul Majeed Abdullah and Barakat, Assem},
title = {Synthesis and SARs study of novel spiro‐oxindoles as potent antiproliferative agents with CDK‐2 inhibitory activities},
journal = {Archiv der Pharmazie},
year = {2023},
doi = {10.1002/ardp.202300185}
}
EUVIMED